For Price Hikes Without New Data, 3 Drugs With Approved Biosimilars Are Key Offenders, Says ICER
October 9th 2019The Institute for Clinical and Economic Review (ICER) has issued its first annual report on unsupported price increases for US drugs. The report found that 3 brand-name biologics that have FDA-approved biosimilars—adalimumab, rituximab, and pegfilgrastim—have had significant price increases that were not supported by new clinical evidence.
Anti-TNF Therapies Reduce Alzheimer Risk in RA, Psoriasis, Early Study Says
October 9th 2019A recent preliminary study examined whether adults treated with anti–tumor necrosis factor agents (anti-TNFs) had reduced the risk of Alzheimer disease, and found that patients with rheumatoid arthritis (RA) and psoriasis who were treated with anti-TNFs had a lower risk of developing the incurable neurocognitive disorder.
New Anti-VEGF Agent, Brolucizumab, Cleared by FDA to Treat AMD
October 8th 2019Even as biosimilars of anti–vascular endothelial growth factor (anti-VEGF) agents are coming to market and advancing through the pipeline, a new agent that may have substantial benefits for patients with wet age-related macular degeneration (AMD) has been approved by the FDA: brolucizumab, which sponsor Novartis will sell as Beovu.
Nevada Tells 21 Diabetes Drug Makers They Owe $17.4 Million for Violating Transparency Law
October 7th 2019The state’s Department of Health and Human Services this week sent letters to firms that did not provide required information about production costs, marketing and advertising costs, patient assistance programs, wholesale acquisition costs, and historical increases, among other information.
Pediatric Patients and Their Families Report Unique Concerns When It Comes to Biosimilar Switching
October 7th 2019According to the authors, while many anticipated that most major concerns about the switch to biosimilar adalimumab would relate to safety and efficacy, more prevalent concerns were related to device type, the presence of a citrate, or the color of the product.
Eye on Pharma: Celltrion and Juno Team Up to Market Biosimilars in Australia
October 6th 2019Biosimilar developer Celltrion and Juno Pharmaceuticals announced that they have entered into a comarketing partnership for Celltrion’s trastuzumab biosimilar, Herzuma, and its rituximab biosimilar, Truxima, in the Australian market.
UK Opposition Party Proposes Compulsory Licensing to Develop Cheaper Drugs
October 5th 2019The Labour party, the United Kingdom’s official opposition party, revealed during a conference that it plans to reduce the cost of drugs by setting up a government-owned generic drug manufacturer that would supply medicine to the National Health Service and by employing compulsory licensing to use drug makers’ intellectual property to develop generics.
As the White House Touts Progress on Drug Prices, Groups Call for Action on Biosimilars
October 4th 2019This week, the White House has been signaling that it sees progress on the problem of high drug prices, a subject of such concern to the administration that it released the “American Patients First” blueprint for reducing drug prices in 2018. However, some groups are calling for redoubled efforts on encouraging biosimilars as a way to generate savings and relieve the burden of high drug costs on the healthcare system and on patients.
Price Transparency to Lower Spending: Difficult but Possible, Authors Say
October 4th 2019There are some health policy experts who believe that price transparency will work to bring down healthcare spending. In a recent article in JAMA, Gilbert Benavidez, MPH, and Austin Frakt, PhD, say that the notion has rarely worked, but they suggest there are 2 ways that it might.
Head-to-Head Study Shows Ixekizumab Outperforms Adalimumab in Psoriatic Arthritis
October 3rd 2019Could adalimumab and its biosimilars become a less attractive option for treating some inflammatory diseases in the face of new therapeutic choices like interleukin-17 inhibitors? In the case of ixekizumab, a recent head-to-head study versus adalimumab showed that the newer product was superior in terms of improving joint and skin disease in patients with psoriatic arthritis.
Biocon and Mylan Launch Insulin Glargine Biosimilar in Australia
October 3rd 2019Biocon and Mylan have launched their biosimilar insulin glargine, Semglee, in Australia. The general schedule for Semglee lists the biosimilar as “a-flagged,” a designation that allows a product to be substituted at the pharmacy level without consulting with the prescribing physician.
AARP, HHS File Briefs in DTC Case Over Drug Prices
October 2nd 2019The case over whether drugmakers can be compelled to disclose pharmaceutical prices in direct-to-consumer (DTC) television advertisements continues in the US Court of Appeals for the District of Columbia, with HHS appealing and AARP and the AARP Foundation filing an amicus brief this week in Merck & Co. Inc. et al v US Department of Health and Human Services et al.
Novartis to Seek a Fourth Indication for Secukinumab
October 2nd 2019Drug maker Novartis announced that it will seek a fourth indication—nonradiographic axial spondyloarthritis (nr-axSpA)—for its secukinumab (Cosentyx) in the United States after its phase 3 PREVENT trial met its 52-week primary end point.
COA Issues Policy Statement on Step Therapy in Cancer Care
October 1st 2019Step therapy, which requires that patients try the payer’s preferred treatment before the one a physician recommends, jeopardizes the health of patients with cancer by delaying treatment and creating unnecessary barriers, according to a recent position statement from the Community Oncology Alliance (COA).
State-Level Drug Price Transparency Laws Miss the Mark, Say Researchers
October 1st 2019While policy makers have hailed drug price transparency laws as steps toward bringing down the high cost of drugs for US patients, questions remain as to how effective these laws are at achieving their aims. Now, in a research letter published in JAMA Network Open, researchers say that these laws are largely ineffective at revealing true transaction prices for drugs.
New Data Reported for Trastuzumab Biosimilars CT-P6 and HLX02 at ESMO 2019
October 1st 2019Biosimilar trastuzumab is becoming a feature of the biosimilar landscape in both Europe and the United States, with 5 agents (Herzuma, Kanjinti, Ontuzant, Ogivri, and Trazimera) approved in both territories and with additional biosimilars in the drugmakers’ pipelines. During the European Society for Medical Oncology (ESMO) Congress 2019, held in Barcelona, Spain from September 27 to October 1, researchers reported new data from phase 3 studies of 2 such biosimilar products.
Can Congress Speed Biosimilars to Market by Limiting Patent Litigations?
September 30th 2019Using data compiled for BiologicsHQ.com, we analyzed 2 bills that propose changes to patent litigation by limiting the number of patents a reference product sponsor can assert in a patent litigation to see how many biosimilar cases they would have impacted so far and whether they would really help bring biosimilars to market sooner.
ESMO 2019 Features Data on Biosimilar Pegfilgrastim and Filgrastim
September 30th 2019During the European Society for Medical Oncology (ESMO) Congress 2019, researchers provided a detailed look at a 3-treatment, 6-sequence crossover study for a pegfilgrastim biosimilar, and a separate team presented on the use of biosimilar filgrastim in patients who are being given chemotherapy regimens that involve a rest period of up to 14 days.
Pfizer Confirms It Plans to Launch Bevacizumab Biosimilar on December 31
September 30th 2019In an email to The Center for Biosimilars®, a Pfizer representative said that, after having agreed to the terms of a settlement with Genentech and Roche that provides the biosimilar developer with global licenses for its product, Pfizer plans to launch its biosimilar bevacizumab, Zirabev, in the US market on December 31, 2019.
During ESMO 2019, Researchers Report That Biosimilar SB8 is Equivalent to Avastin in Best ORR
September 28th 2019During this week’s European Society for Medical Oncology (ESMO) Congress 2019, held September 27 to October 1 in Barcelona, Spain, a research team presented findings from a phase 3 trial of Samsung Bioepis' SB8, a proposed bevacizumab biosimilar referencing Avastin.